Chen Fang

Dr. Chen Fang

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
YHYun Huang
Yun Huang
SLSi-Cheng Li
Si-Cheng Li
JHJi Hu
Ji Hu
HRHai-Bin Ruan
Hai-Bin Ruan
HGHe-Ming Guo
He-Ming Guo
CFChen Fang
Chen Fang

27 March 2019 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
XDXin Ding
Xin Ding
CFChen Fang
Chen Fang
XLXiang Li
Xiang Li
YCYongjun Cao
Yongjun Cao
QZQilin Zhang
Qilin Zhang
XZXia Zhang
Xia Zhang
To compare neurocognitive functioning of Type 1 diabetic mellitus (T1DM) and healthy adults, and explore risk factors of cognitive dysfunction of T1DM patients, especially the association between cognitive impairment and diabetic peripheral neuropathy (DPN). Seventy T1DM (age: 32.17 ± 9.57 yr., duration: 8.99 ± 7.02 yr) patients and 48 healthy volunteers were included. All subjects received evaluation of MMSE and MoCA scales. Cognitive function of T1DM patients was evaluated in different cognitive domains. Risk factors affecting cognitive function were further explored. Three patients with educational level ≤ 6-year were excluded from final analysis. Scores of both MMSE (28.4 ± 1.7 vs. 29.1 ± 1.0, P = 0.005) and MoCA scales (25.9 ± 2.7 vs.27.1 ± 2.4, P = 0.017) in T1DM group were lower than that in control group. For MMSE scale, scores of orientation (9.60 ± 0.79 vs.9.87 ± 0.39, P < 0.001) and language function (8.56 ± 0.65 vs.8.83 ± 0.38, P < 0.001) in T1DM groups were lower than that in control group. For MoCA scale, scores of attention and concentration (2.30 ± 0.74 vs.2.57 ± 0.58, P < 0.001), visuospatial/executive function (4.32 ± 0.91 vs.4.64 ± 0.63, P < 0.001), memory (2.96 ± 1.50 vs.3.66 ± 1.28, P < 0.001), language function (5.71 ± 0.69 vs.5.87 ± 0.39, P = 0.007), and abstraction (1.55 ± 0.68 vs.1.82 ± 0.42, P < 0.001) were lower in T1DM group than that in control group. Logistic regression showed age, fasting C peptide, educational level and nerve conduction velocity (NCV) were associated with cognitive dysfunction diagnosed by MoCA scores for the patients with type 1 diabetes. T1DM adults had mild to moderate cognitive impairment, mainly presenting as dysfunctions of attention and concentration, visuospatial/executive, language, and abstraction. In addition to age, fasting C peptide level, and educational level, DPN, as a diabetic complication, was identified to be associated with cognitive impairments.

11 November 2018 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
CQChenyue Qian
Chenyue Qian
HGHeming Guo
Heming Guo
XCXiaohong Chen
Xiaohong Chen
ASAiming Shi
Aiming Shi
SLSicheng Li
Sicheng Li
CFChen Fang
Chen Fang
Aims. The programmed death- (PD-) 1/PD-1 ligand (PD-L) pathway plays an important role in regulating T cell activation and maintaining peripheral tolerance. Accumulated studies showed that PD-1/PD-L1 pathway was involved in the development of type 1 diabetes (T1DM). Since the genetic background of type 1 diabetes differs greatly among the different population, we aim to investigate the association of genetic polymorphisms in PD-1 and PD-L1 with T1DM susceptibility in Chinese population.Methods. In total, 166 T1DM patients and 100 healthy controls were enrolled into the study. Genomic DNA was extracted from 4 mL peripheral blood samples collected from each subject. Genotyping of 8 selected SNPs of PD-1 and PD-L1 was carried out by the pyrosequencing PSQ 24 System using PyroMark Gold reagents (QIAGEN).Results. SNP rs4143815 in PD-L1 was significantly associated with T1DM. People carrying the C allele of rs4143815 suffering less risk of T1DM and T1DM patients with G/G genotype showed higher levels of autoantibody (AAB) positive incidence compared with C allele carriers. No significant associations were found in other SNPs.Conclusions. Our results indicate that rs4143815 of PD-L1 is significantly associated with T1DM and may serve as a new biomarker to predict the T1DM susceptibility.

22 November 2017 in Diabetologia
Verified
Journal Article
Closed access
PDF file
YHYun Huang
Yun Huang
XCXin Chen
Xin Chen
XCXiaohong Chen
Xiaohong Chen
YFYu Feng
Yu Feng
HGHeming Guo
Heming Guo
JHJi Hu
Ji Hu

1 November 2018 in Medicine
Verified
Journal Article
Open access
SLSicheng Li
Sicheng Li
YZYi Zhang
Yi Zhang
ZSZhichun Sun
Zhichun Sun
JHJi Hu
Ji Hu
CFChen Fang
Chen Fang
Rationale: Programmed cell death-1 protein (PD-1) antibody is an immune-checkpoint inhibitor that triggers anti-tumor response by enhancing immune response. Although PD-1 antibody has been reported effective in some malignant tumor, it can also induce significant immune-related adverse events (irAEs) such as autoimmune diabetes. Patient concerns: A 67-year-old male patient with non-small cell lung cancer (NSCLS) presented with polydipsia, polyuria, weakness, and weight loss after use of anti-programmed cell death-1 antibody therapy. Hyperglycemia, high serum ketone, low bicarbonate and high anion gap were compatible with the criteria of diabetic ketoacidosis (DKA). Diagnoses: Autoimmune diabetes and diabetic ketoacidosis (DKA). The presence of low serum titers of c-peptide, high blood glucose together with diabetic ketoacidosis (DKA) that occurs shortly after the use of pembrolizumab strongly supported the diagnosis of anti-PD-1 induced autoimmune diabetes. Interventions: The patient stopped using pembrolizumab while continuous subcutaneous insulin infusion (CSII) was started at the same time. The insulin infusion was switched to multiple daily injection (MDI) after he was discharged from hospital. Outcomes: The patient is now a well-controlled insulin-dependent patient with palliative care of NSCLS. Lessons: Autoimmune diabetes induced by anti-programmed cell death-1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) therapy is a rare, but life threatening immune-related side effect. Physicians should closely monitor diabetes-related indexes of patients who have been undergoing the treatment of anti-PD-1/PD-L1 therapy.

8 January 2020 in Endocrine
Verified
Journal Article
Closed access
PDF file
HGHeming Guo
Heming Guo
YSYingxiao Shen
Yingxiao Shen
YKYing-Hong Kong
Ying-Hong Kong
SLSicheng Li
Sicheng Li
RJRong Jiang
Rong Jiang
JHJi Hu
Ji Hu